JPS6185951A - Membrane type serum separation system - Google Patents
Membrane type serum separation systemInfo
- Publication number
- JPS6185951A JPS6185951A JP59208674A JP20867484A JPS6185951A JP S6185951 A JPS6185951 A JP S6185951A JP 59208674 A JP59208674 A JP 59208674A JP 20867484 A JP20867484 A JP 20867484A JP S6185951 A JPS6185951 A JP S6185951A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- membrane
- pressure
- line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000926 separation method Methods 0.000 title claims description 40
- 239000012528 membrane Substances 0.000 title claims description 36
- 210000002966 serum Anatomy 0.000 title 1
- 239000008280 blood Substances 0.000 claims description 56
- 210000004369 blood Anatomy 0.000 claims description 55
- 210000003743 erythrocyte Anatomy 0.000 claims description 17
- 239000012141 concentrate Substances 0.000 claims description 15
- 230000036770 blood supply Effects 0.000 claims description 12
- 210000004204 blood vessel Anatomy 0.000 claims description 9
- 230000032258 transport Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 85
- 206010018910 Haemolysis Diseases 0.000 description 8
- 230000008588 hemolysis Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002616 plasmapheresis Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012840 feeding operation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明は体外血液循環において血液から血漿のみを分離
し、血液から血漿が分離された赤血球濃厚液を体内に返
送する脱型血漿分離システムに関する。[Detailed Description of the Invention] <Industrial Application Field> The present invention relates to a detyped plasma separation system that separates only plasma from blood during extracorporeal blood circulation and returns the red blood cell concentrate from which plasma has been separated into the body. .
〈従来の技術〉
膜型血漿分離器を使用した１摸型血漿分離システムは分
離血漿中に血小板等の有形成分を含有しないので最も有
効な方法であるが、血漿が比較的大きなポアサイズの膜
を使用した膜分離によって分離されるので膜分離が過大
な血液圧力下または圧変動下で行われるとき溶血現象を
生じることがある。そのため与えられた模条件の下で血
漿分離能を決定する分離膜の両側の差圧としてのトラン
スメンブレン圧の制御を行うこ七によって溶血現象を解
消する手段が採用されている。その構成け１摸型血マ分
離器の下流の血液ラインにクランプを配置し、クランプ
の開閉によって前記模型分離器にポンプ輸送される血液
の圧力を調整してトランスメンブレン圧を制御しようと
するものであった。<Prior art> A one-plate plasma separation system using a membrane-type plasma separator is the most effective method because the separated plasma does not contain formed components such as platelets. When membrane separation is performed under excessive blood pressure or pressure fluctuations, hemolysis may occur. Therefore, a method has been adopted to eliminate the hemolysis phenomenon by controlling the transmembrane pressure, which is the differential pressure on both sides of the separation membrane, which determines the plasma separation ability under given simulated conditions. Its structure is to control the transmembrane pressure by placing a clamp in the blood line downstream of the model blood separator and adjusting the pressure of the blood pumped to the model separator by opening and closing the clamp. Met.
〈発明が解決しようとする問題点〉
上記の従来技術においてトランスメンブレン圧制御が膜
型血漿分離器の下流の血液ラインに配置されたクランプ
の開閉によって行われるために、トランスメンブレン圧
が制御状態にあってもトランスメンブレン圧を高く設定
するとき、必然的に血液側圧力も増加されねばならない
。そのため従来技術＆ｎおいては溶血現象を生じ易く、
溶血成分は前記模型分離器に装備された分離膜を血漿と
とも知通過し、分離された血漿を汚染する。<Problems to be Solved by the Invention> In the prior art described above, the transmembrane pressure is controlled by opening and closing a clamp placed in the blood line downstream of the membrane plasma separator, so the transmembrane pressure cannot be controlled. Even if the transmembrane pressure is set high, the blood side pressure must necessarily be increased. Therefore, the conventional technology tends to cause hemolysis,
The hemolytic components pass through the separation membrane installed in the model separator together with the plasma, contaminating the separated plasma.
この汚染は献血によって採取される分離血漿を血液製剤
または皿桑製剤の原料として使用するときＫは許容され
ないものであり、さらに本発明者等が先に発表した採［
１１１者の１′先川を軽減する申↑ド（膜分離型血漿採
取システムによる血漿分離（でおハては、該分離か間欠
的に行われるので血凄分離嘆圧の変動が大であり溶血発
生の危険性がさら１て増大する。This contamination is unacceptable when separated plasma collected from blood donation is used as a raw material for blood products or plate preparations.
111 patients, plasma separation using a membrane separation type plasma collection system (in this case, since the separation is performed intermittently, there are large fluctuations in the blood pressure during blood separation). The risk of hemolysis occurring is further increased.
また血漿交換を必要とする患者に対する膜分離による血
漿交換治療においては、治療時−１か長いので溶血に原
因する血球ロスの影響が著るしく増大する。Furthermore, in plasmapheresis treatment using membrane separation for patients requiring plasmapheresis, the treatment time is -1 long, so the effect of blood cell loss due to hemolysis increases significantly.
く問題点を解決するための手段〉
本発明は上記の問題点を解決するためになされたもので
あって、血漿分離膜を備えた膜型血漿分離器と、該膜型
血漿分離器に採血者の血管から血液をポンプ輸送する送
血ラインと、前記Ｎ送された血液からｍＪ記１漠型分離
器において１）ｉＪ ８己血漿分離膜を通過した血漿が
分離された赤血球−ノ！メ液を前記採血者の血管に返送
する返送ラインと、前記分離された血漿を系外に輸送す
る血漿ラインと、前記分離膜を経由するトランスメンブ
レン圧制御装盪とよりなる。Means for Solving the Problems> The present invention has been made to solve the above problems, and includes a membrane-type plasma separator equipped with a plasma separation membrane, and a method for collecting blood into the membrane-type plasma separator. A blood supply line that pumps blood from the patient's blood vessels, and a red blood cell from which plasma that has passed through a plasma separation membrane is separated from the blood that has been sent through a mJ-1 type separator. The system consists of a return line for returning the blood plasma to the blood collector's blood vessel, a plasma line for transporting the separated plasma to the outside of the system, and a transmembrane pressure control device that passes through the separation membrane.
く作用〉
上記、膜型血漿分離器を経由する体外血液循環において
前記分離膜を通過する血漿分離が行われ、その間、前記
トランスメンブレン圧は前記血漿ラインの内圧調整によ
って設定値どおりに制御される。In the above-mentioned extracorporeal blood circulation via the membrane-type plasma separator, plasma separation passing through the separation membrane is performed, and during that time, the transmembrane pressure is controlled to a set value by adjusting the internal pressure of the plasma line. .
〈実りや１汐り〉 以下本発明の実施例を図面に基ついて説明する。〈Fruit and one tide〉 Embodiments of the present invention will be described below with reference to the drawings.
第１図は２針式膜型血漿分離ノステムの流路系図である
。ドナーＤの両腕のそれぞれの血管に留置針１，１′が
留置される。送血側の留置針１からの血液は送血ライン
２を経て血漿分離膜を装備した膜型血漿分離器３に送血
ポンプ４の作動によってポンプ輸送される。この送血中
に抗凝血剤容器５から抗凝血剤ライン６を経て抗凝血剤
が前記送血ライン２内の血液に規定の割合で添加される
。抗、疑血剤としてＡＣＤ液を使用するとき血流量のる
が添加され、重力流添加、送血ポンプ４を図示の２連式
ポンプとし、このポンプ４に装備される前記送血ライン
２と抗凝血剤ライン６の内断；ｌ！］積を規定比、例え
ばＡＣＤを使用するときは９対ｌとした同一ポンプ４に
よる同時輸送、または送血用と抗凝血剤輸送用の独立し
た２台のポンプの使用等によって抗凝血剤の添加が行わ
れる。前記膜型血漿分離器３に輸送された抗凝血化血液
は、この分離器３に装備された血漿分離膜を通過する血
イととこの分離膜を通過しない赤血球濃厚液と・：て分
離される。血液から血漿か分離されたこの赤血球濃厚液
は返送ライン７および返送側の前記留置針１′を経て前
記ドナーＤの他の血管内に返送される。FIG. 1 is a flow path diagram of a two-needle membrane type plasma separation system. Indwelling needles 1 and 1' are placed in blood vessels in both arms of donor D, respectively. Blood from the indwelling needle 1 on the blood feeding side is pumped through a blood feeding line 2 to a membrane plasma separator 3 equipped with a plasma separation membrane by the operation of a blood pump 4. During this blood supply, an anticoagulant is added to the blood in the blood supply line 2 from the anticoagulant container 5 via the anticoagulant line 6 at a prescribed ratio. When ACD liquid is used as an anti-blood suspect agent, blood flow rate is added and gravity flow is added. Internal rupture of anticoagulant line 6; l! ] Anticoagulation can be achieved by simultaneous transportation using the same pump 4 with the product in a specified ratio, for example, 9:1 when using an ACD, or by using two independent pumps for blood delivery and anticoagulant delivery. The addition of the agent is carried out. The anticoagulated blood transported to the membrane-type plasma separator 3 is separated into blood that passes through the plasma separation membrane equipped in this separator 3 and red blood cell concentrate that does not pass through this separation membrane. be done. This red blood cell concentrate, in which plasma has been separated from blood, is returned into the other blood vessel of the donor D via the return line 7 and the indwelling needle 1' on the return side.
前記ａ漿は血漿ライン８を経て好ましくは血液バッグ形
式の血漿容器９に収容され所定量の採梨が行われ６まで
上記サイクルが繰返される。The a-plasma passes through a plasma line 8 and is stored in a plasma container 9, preferably in the form of a blood bag, and a predetermined amount of the plasma is collected, and the above cycle is repeated up to 6.
図中、１０は前記返送ライ／７の下流に配備された一般
に超音波方式の気泡検知器であり、６１１記返送ライン
７内の気泡検知時に、前記送血ポンプ４を停止させて前
記ドナーＤを空気塞栓から保獲するものであり、１１と
１２とはそれぞれ前記送血ライン２と返送ライ／７に介
在するエアトラップであり、それぞれのライン２．７の
内圧を表示し圧力信号を出力する圧力計ＰＩ、Ｐ２を備
える。In the figure, 10 is a generally ultrasonic bubble detector disposed downstream of the return line 7, and when air bubbles are detected in the return line 7 at 611, the blood pump 4 is stopped and the donor D 11 and 12 are air traps interposed in the blood supply line 2 and return line/7, respectively, which display the internal pressure of each line 2 and 7 and output a pressure signal. It is equipped with pressure gauges PI and P2.
Ｐ３ｉま前記膜型血漿分離器３内の前記分離膜の血染側
の圧力を指示し圧力信号を出力する圧力計である。P3i is a pressure gauge that indicates the pressure on the blood-stained side of the separation membrane in the membrane-type plasma separator 3 and outputs a pressure signal.
上記構成に加えて本実施列は前記圧力計ＰＩ。In addition to the above configuration, this embodiment includes the pressure gauge PI.
Ｐ２．Ｐ３からの圧力信号によりトランスメツブレン圧
、すなわち（Ｐ ｌ ＋ Ｐ ２ ） ／ ２− Ｐ
３を計算し、この計算値か設定値どおりに制御させるよ
うに前記血漿ライ／８の内圧を調整するだめの信号を出
力する制御装置１３を備える。P2. The pressure signal from P3 determines the transmetubrene pressure, i.e. (P l + P 2 ) / 2- P
3 and outputs a signal for adjusting the internal pressure of the plasma lye/8 so as to control the calculated value or the set value.
この制御装置１３は前記トランスメンブレン圧計算値に
基ついて前記血漿ライン８に配備されたクランプ１４ま
たは装備されていれば血漿ポンプ１５を作動させてトラ
ンスメンブレン圧を設定値どおり（で制御する。すなわ
ちトランスメンブレン圧計算値が設定値よりも高ければ
、前記クランプ１４を開くか、あるいは前記血漿ポンプ
１５の回転を上げ、前記計算値が低すぎれば前記クラン
プ回転を下げる。一般に前記クランプ１４は前記血漿タ
イプ８に陽圧を与えるのでトランスメンブレン圧の設定
値が相対的に低いときに適用され、前記血漿ポンプ１５
は前記血漿ライン８に陰圧を与えることができるのでト
ランスメンブレ／圧の設定値か相対的に高いときに使用
される。また前記血漿ライン８に前記クランプ１４と、
該クランプ１４の下流の前記血漿ポンプ１５との両者を
配備し、前記血漿分離器３の濾過膜の目詰りがなく分離
抵抗の低い採漿初期の段階では前記クランプ１４の開放
下に前記血漿ポンプ１５を一定スピードで回転させて低
トランスメンブレン圧下での高効率の血漿分離を行い、
前記分離膜上への血液からの蛋白沈着等に原因する該分
′ａ膜の分離抵抗の上昇に伴ってトランスメンブレン圧
が上昇してから前記クランプ１４によるトランスメンブ
レン圧制御に移行してもよい。さらにトランスメツブレ
ン圧を経時的に上昇させるプログラミングによって、前
記分離膜の目詰りに原因する血染分離能の低下を補償す
ることもできる。Based on the calculated transmembrane pressure value, the control device 13 operates the clamp 14 disposed on the plasma line 8 or the plasma pump 15, if equipped, to control the transmembrane pressure according to the set value. If the calculated transmembrane pressure is higher than the set value, the clamp 14 is opened or the rotation of the plasma pump 15 is increased, and if the calculated value is too low, the clamp rotation is decreased. Since positive pressure is applied to type 8, it is applied when the set value of transmembrane pressure is relatively low, and the plasma pump 15
Since it can apply negative pressure to the plasma line 8, it is used when the set value of the transmembrane/pressure is relatively high. Further, the clamp 14 is attached to the plasma line 8,
Both the plasma pump 15 and the plasma pump 15 are provided downstream of the clamp 14, and in the initial stage of sample collection when the filtration membrane of the plasma separator 3 is not clogged and the separation resistance is low, the plasma pump 15 is placed downstream of the clamp 14 while the clamp 14 is open. 15 at a constant speed to perform highly efficient plasma separation under low transmembrane pressure.
The transmembrane pressure may be controlled by the clamp 14 after the transmembrane pressure increases due to an increase in the separation resistance of the membrane due to protein deposition from blood on the separation membrane. . Furthermore, by programming the transmembrane pressure to increase over time, it is also possible to compensate for the decrease in blood stain separation capacity caused by clogging of the separation membrane.
トランスメツブレン圧として前記の送血ライン２の内圧
と返送ライノアの内圧の平均値、および＠築うイン８の
内圧の差圧を採用することが好ましいか、上記平均（直
の代りに前記送血ライン２の内圧あるいは返送ライン７
の内圧の何れかを代表として採用することもできる。Is it preferable to use the average value of the internal pressure of the blood supply line 2 and the internal pressure of the return liner, and the differential pressure of the internal pressure of the @build in 8 as the transmetubrene pressure? Internal pressure of blood line 2 or return line 7
It is also possible to adopt any of the internal pressures as a representative.
本実施例において膜型血漿分離器として内径２７０ミク
ロン、肉厚８０ミクロン、有効膜面積０゜２５ｙｙ１’
、有効長１６３ｍｒｓ、最大ポアサイズ０．４ミクロ／
のセルローストリアセテート中空糸を装備した中空糸タ
イプのものを使用し、送部流量４５、／ ／ 分、抗？
疑血剤としてのＡＣＤ液流量５ ｌＩｅ ７分、トラン
スメンブレン圧制御範囲０〜２０ ｍｍＨｇ〕条注の下
で５００ ｍｌの血漿を３３分で採取することができ、
溶血ンブかりでなく凝血も認められず、ドナーに何等異
常は発見されなかった。In this example, the membrane type plasma separator has an inner diameter of 270 microns, a wall thickness of 80 microns, and an effective membrane area of 0°25yy1'.
, effective length 163 mrs, maximum pore size 0.4 micro/
A hollow fiber type equipped with cellulose triacetate hollow fibers was used, with a flow rate of 45, / / min, and a resistance to
500 ml of plasma can be collected in 33 minutes under ACD fluid flow rate of 5 lIe for 7 minutes as a blood suspect agent, transmembrane pressure control range of 0 to 20 mmHg],
No hemolysis or blood clots were observed, and no abnormality was found in the donor.
第２図はドナーの負担を軽減させるための単針成膜型血
漿分離ノステムの流路系図であり、第１図と共通の部分
は同一符号で示される。ドナーＤの片腕の血管に留置針
１が留置される。この留置針１からの血液は前記実施例
と同様に抗凝血化されて模型口１１漿分離器３にポンプ
ψｉ＋５送され、この分離器３によって血漿と赤血球濃
厚液とシて分離される。分離された血漿は血漿ライン８
を経て血桑容器９に輸送される。＠言己抗凝血化血液か
ら血漿が分離された赤血球濃厚液は返送ライン７に連通
ずる好ましくは血液バッグ形式の赤血球濃厚ｔＬｇ器１
６に貯留される。この赤血球濃厚液容器１６は該容器を
計量する計量手段１７を備える。この計量手段は図示の
スプリング式の懸吊タイプの秤または台秤等の重量方式
、あるいは前記赤血球Ｃｌ−１液容器１Ｇ内の液レベル
を検知する光学式ｆたは超音波式等の容量方式の何れで
あってもよく、規定の上限および下限において検知信号
を出力する。FIG. 2 is a flow path diagram of a single-needle membrane-forming plasma separation system to reduce the burden on donors, and parts common to those in FIG. 1 are indicated by the same symbols. An indwelling needle 1 is placed in a blood vessel in one arm of donor D. The blood from the indwelling needle 1 is anticoagulated in the same way as in the previous embodiment and pumped ψi+5 to the model port 11 and the plasma separator 3, where it is separated into plasma and red blood cell concentrate. The separated plasma is transferred to plasma line 8.
The blood is then transported to the blood mulberry container 9. The red blood cell concentrate from which plasma has been separated from the anticoagulated blood is communicated with the return line 7. The red blood cell concentrate tLg device 1 is preferably in the form of a blood bag.
6 is stored. This red blood cell concentrate container 16 is equipped with measuring means 17 for weighing the container. This measuring means may be a gravimetric method such as a spring type suspension type scale or a platform scale as shown in the figure, or a capacitive method such as an optical method or an ultrasonic method that detects the liquid level in the red blood cell Cl-1 liquid container 1G. Either may be used, and a detection signal is output at the specified upper and lower limits.
前記赤血球濃厚液容器１６の計量値が上限に達したら、
前記計量手段１７から上限検知信号が間欠作動制御装置
１８に出力される。この間欠作動制御装置１８は送血ポ
ンプ４に信号出力してこのポンプ４を停止せしめるとと
もに、前記赤血球濃厚液容器１６の下流側の前記返送ラ
イン７に配備され、送血作動時に停止していた返送ポン
プ１９を作動させる。この送血停止下の赤血球濃厚液返
送時には送血圧がＯとなるのでトランスメンブレン圧制
御装装置１３はクランプ１４を閉じるか、あるいは装備
されていれば血漿ポンプ１５を停止させる。When the measured value of the red blood cell concentrate container 16 reaches the upper limit,
An upper limit detection signal is output from the measuring means 17 to the intermittent operation control device 18. This intermittent operation control device 18 outputs a signal to the blood pump 4 to stop the pump 4, and is installed in the return line 7 on the downstream side of the red blood cell concentrate container 16, and is stopped during the blood feeding operation. The return pump 19 is activated. When the red blood cell concentrate is returned while the blood supply is stopped, the pumping pressure becomes O, so the transmembrane pressure control device 13 closes the clamp 14 or stops the plasma pump 15 if equipped.
前記赤血球濃厚液容器１６の内各量が減少して規定の下
限計量値になると前記計量手段１７からの下限信号に基
づいて前記送血ポンプ４が作動し、前記返送ポンプ１７
が停止して血漿採取と赤血球濃厚液の貯留に移行し、こ
の血漿採取の間のトランスメンブレン圧は前記クランプ
１４または装備されていれば血漿ポンプ１５の作動によ
って設定値どおりに制御され、以下上記のサイクルが繰
返される。なお図中２０は圧力計Ｐ４を備えたエアトラ
ップである。When each amount in the red blood cell concentrate container 16 decreases to a specified lower limit measurement value, the blood pump 4 is activated based on the lower limit signal from the measuring means 17, and the return pump 17 is activated.
is stopped and shifts to plasma collection and red blood cell concentrate storage, during which the transmembrane pressure is controlled according to the set value by the operation of the clamp 14 or, if equipped, the plasma pump 15, as described above. The cycle is repeated. Note that 20 in the figure is an air trap equipped with a pressure gauge P4.
本実施例において、膜型血漿分離器３として前記第１の
実ＪＡ Ｎ ？て示した中空糸タイプのものを使用し、
送血流量を４５ｄ／分、ＡＣＤ液流量を５＃Ｉ／／分、
トラ／スメンブレノ圧制御範１用を０〜３０ｍａＨｇ、
計量上限値をネット１２０ｇ、計量Ｆ退位を２０ｇＫ設
定したとき、１色面約３分、返ｊＡ 、７．１２分のサ
イクルの下で送血時血漿流量約１５ ｍ１７分が得られ
、５６分間で５００ Ｍｌつ皿箋を採取することができ
、溶面、・疑血およびドナ一つ異′帛′仁見出せなかっ
た。In this embodiment, the membrane type plasma separator 3 is the first real JAN? Use the hollow fiber type shown in
The blood flow rate was 45 d/min, the ACD fluid flow rate was 5 #I/min,
For pressure control range 1, 0 to 30 maHg,
When the upper limit of measurement was set to 120g net and the weight loss was set to 20gK, a plasma flow rate of approximately 15 m17 minutes was obtained during blood transfer under a cycle of approximately 3 minutes for one color plane, 7.12 minutes for return, and 56 minutes for 56 minutes. A 500 ml plate was collected, and no lysed surface, no suspicious blood, and no abnormal tissue was found.
第３図は本発明に基つく血染交換治療／ステムの流路系
図であり、リウマチ様関節炎等つ治療を目的とするもの
である。図面において第１１Ａと４２図と共通の部分は
同一符号で示される。管、者Ｐの両腕のそれぞれの血管
に留置針１．１′が留置される。送血側の留置針１から
の血液は送直ポンプ４の作動によって莫型血漿分離ＦＳ
３に揃速される。FIG. 3 is a flow path diagram of the blood stain exchange treatment/stem based on the present invention, and is intended for treatment of rheumatoid arthritis and the like. In the drawings, parts common to FIGS. 11A and 42 are designated by the same reference numerals. An indwelling needle 1.1' is placed in each blood vessel of person P's arms. The blood from the indwelling needle 1 on the blood sending side is separated into Mo-type plasma by the operation of the direct pump 4.
The speed is adjusted to 3.
この送血中にンリンジボンプ５′から抗・疑血剤、例え
ばヘパリンが抗凝血剤ライ／６を経て前記送血ライン２
中の血液に規定比で添加される。この抗凝血化血液は前
記膜型血漿分離器３において皿梁と赤＋ｒｎ球濃厚液と
に分離される。この赤血球濃厚液は返送ライン７と返送
側の前記留置針１′を経て患者Ｐの血管に返送される。During this blood supply, an anti-suspect blood agent, such as heparin, is passed from the blood pump 5' to the blood supply line 2 through the anticoagulant Ly/6.
It is added to the blood in a specified ratio. This anticoagulated blood is separated in the membrane type plasma separator 3 into a dish beam and a red+rn bulb concentrate. This red blood cell concentrate is returned to the blood vessel of the patient P via the return line 7 and the indwelling needle 1' on the return side.
前記膜型血漿分離器３；てよって分離された病因物質を
含有する血漿は血漿ライン８を経て血漿容器９に輸送さ
れる。符号２１は交換ポンプであって、この交換ポンプ
２ｉｔ−を前記血漿ライン８を装備して血漿を輸送する
とともに、エアトラップ１２と気泡検出器１０との間の
前記返送ライン７と、好ましくは血液バッグ形式の補充
液容器２２とを接続する補充液ライ／２３をも装備して
補充液をも輸送するための２連式ポンプである。この交
換ポンプ２１に装備された前記血漿ライン８と補充液ラ
イン２３とは同−内断面をもち、前記血漿容器９に流入
する血漿流−：Ｊｌと理論的て同じ流量で補充液容器２
２から補充液を前記返送ライン７に供給し、この補充液
はこの返送ライン７内の赤血球濃厚液と合流して前記留
置針１′を経て前記患者Ｐの胆管に与えられる。Plasma containing pathogenic substances separated by the membrane-type plasma separator 3 is transported to a plasma container 9 via a plasma line 8. Reference numeral 21 denotes an exchange pump, and this exchange pump 2it- is equipped with the plasma line 8 to transport plasma, and is also connected to the return line 7 between the air trap 12 and the bubble detector 10, and preferably connects the blood This is a dual pump that is also equipped with a replenisher line/23 connected to a bag-type replenisher container 22 to transport the replenisher. The plasma line 8 and the replenisher line 23 installed in the exchange pump 21 have the same internal cross section, and the plasma flow flowing into the plasma container 9 is theoretically the same flow rate as Jl.
Replenishment fluid is supplied from 2 to the return line 7, and this replenishment fluid merges with the concentrated red blood cell solution in the return line 7 and is supplied to the bile duct of the patient P via the indwelling needle 1'.
上記の血漿流量と補充液流量とは等しいので、前記沓者
Ｐの体液バランスは継続して維持される。Since the plasma flow rate and the replacement fluid flow rate are equal, the body fluid balance of the person P is continuously maintained.
前記ｔｒｉ 漿ライン８のクランプ１４と交換ポンプ２
１との間に符号２４で示されるエアトラップか設けられ
る。このエアトラップ２４には光学式または超音波式等
の液面検知器２５が配備され、こつ液面検知器２５は前
記エアトラップｚ４内つ皿景レベルを検知し、このレベ
ル検知信号に基つ〈ズ示されない制御装置の作動によっ
て前記交編ポンプ２１の回転が調整され、前記エアトラ
ップ２４内の血漿レベルは一定に制御される。それ１で
よって前記血漿分離器３から流出する血漿流量と同流用
：で、血漿が前記血漿容器９にポンプ輸送される。The clamp 14 of the tri plasma line 8 and the exchange pump 2
An air trap 24 is provided between the 1 and 1. This air trap 24 is equipped with a liquid level detector 25 such as an optical type or an ultrasonic type. The rotation of the alternating pump 21 is regulated by operation of a control device, not shown, and the plasma level in the air trap 24 is controlled to be constant. Plasma is then pumped into the plasma container 9 with the same flow rate of plasma flowing out of the plasma separator 3.
なお符号２６は補充１夜ライ／２３に配備さｈｔ上ヒー
タちって補充液を体温付近まで／ＪＤ熱し、前記患者Ｐ
が受けるンヨツクを解ｌ肖する。血漿交換治療中、トラ
ンスメンブレン圧は前記血漿ライ／８に配備された前記
クランプ１４の開閉によって設定値どおりに制御される
。In addition, reference numeral 26 is installed on the replenishment overnight basis /23 and the heater is heated to heat the replenishment solution to around the body temperature, and the patient P
I will explain the negative feelings that people receive. During plasmapheresis treatment, the transmembrane pressure is controlled according to the set point by opening and closing the clamp 14 located on the plasma line/8.
本実施例において、膜型血漿分離器として内１２７０ミ
クロン、肉厚８０ミクロン、有効模面イ）（０，５ｎｌ
’、有効長１’７０ｍｍ、ｉ％大ポアサイズＯ−￥ミク
ロンのセルａ−ストリアセテート中空糸ｆ Ｉｆ 用し
た中空糸タイプのものを使用し、リウマチ様関筋炎１占
者を次記の条件で治療した結果、１容血や凝血は稔めら
れず、副作用を生じることなく治療の有効性が認められ
た。In this example, a membrane-type plasma separator with an internal diameter of 1270 microns, a wall thickness of 80 microns, and an effective surface area (I) (0.5 nl) was used.
', effective length 1' 70 mm, i% large pore size O-\micron cell a-striacetate hollow fiber fIf using a hollow fiber type, rheumatoid myositis 1 was treated under the following conditions. As a result of the treatment, no one-volume blood or blood clots were formed, and the effectiveness of the treatment was recognized without any side effects.
１５血流計 １００ゴ／分・＼バリア投与
量 ワンショット１０００単位持続注入 計６０
００単位
皿腐交４流量 平均２６ｄ／分トラノスメンブ
レン圧設定範囲 Ｏ〜３０ Ｈｌ Ｈｇ：Ｉｌｌ染廃棄
量 、５０００ ｍｌ！１を喚液量
ａ０３０．ｚ治療時間 ２時
間２０分
〈発明の効果〉
不発明は体外血液循環における１漠型血梁分離器を使用
した血染分離システムにおいて、前記模型ＩＴ…量分離
器に装備された分離膜を継由する血液とＪｎ梁との間の
差圧であるトランスメンブレン圧ヲ皿豪ライン内圧の調
整によって設定［直どおりに制御するものであるから、
１道来の膜型血漿分離器の下流側の血液ラインのクラン
プによって生じる過大な血液側圧力の上昇がなく、その
ため溶血現象発生のおそれを解消し、とくに単針成膜型
血漿分離ノステムにおける間欠作動に原因する溶血現象
の発生防止に有効であり、高品質の血漿を採取すること
かでさる。15 Blood flow meter 100g/min/barrier dose One shot 1000 units continuous infusion Total 60
00 unit dish rotting 4 flow rate Average 26d/min Toranos membrane pressure setting range 0~30 Hl Hg:Ill Dyeing waste amount, 5000 ml! 1 is the amount of liquid pumped
a030. zTreatment time: 2 hours and 20 minutes <Effect of the invention> The non-invention is a blood stain separation system using a vague type blood cell separator in extracorporeal blood circulation, in which the separation membrane installed in the model IT... amount separator is connected. The transmembrane pressure, which is the differential pressure between the flowing blood and the Jn beam, is set by adjusting the internal pressure of the plate.
1. There is no excessive increase in blood pressure caused by the clamping of the blood line on the downstream side of conventional membrane-type plasma separators, which eliminates the risk of hemolysis, and is especially effective for intermittent in single-needle membrane-forming plasma separators. It is effective in preventing the occurrence of hemolytic phenomena caused by operation, and is effective in collecting high-quality plasma.
さらに本発明を血漿交換治療に適用−「るとさ、溶血の
ための血球成分のロスを解消することができる。Furthermore, the present invention can be applied to plasmapheresis therapy, thereby eliminating the loss of blood cell components due to hemolysis.
図面は不発明の実施例に係り、第１図は本発明が適用さ
れた２針式膜型血漿分離／ステムの流路系図、第２図は
単針式嘆型血漿分＠／ステムの流路系図、第３図は本発
明を利用した血漿交換治療／ステムの流路系図であって
、２は送血ライン、３は膜型血漿分離器、７は返送ライ
ン、８は血漿ライン、１３は制御装置、１４Ｉ／ｉクラ
ンプ、１５は血漿ポンプ。
特許出願人 株式会社二ソ７ヨー
代 理 人 弁理士岡田和ガThe drawings relate to embodiments of the invention, and Fig. 1 is a flow path diagram of a two-needle membrane type plasma separation/stem to which the present invention is applied, and Fig. 2 is a flow path diagram of a single-needle membrane type plasma separation/stem. Figure 3 is a flow diagram of the plasmapheresis treatment/stem using the present invention, in which 2 is a blood supply line, 3 is a membrane plasma separator, 7 is a return line, 8 is a plasma line, 13 14 is a control device, 14 is an I/i clamp, and 15 is a plasma pump. Patent applicant: Niso7yo Co., Ltd. Agent: Waga Okada, patent attorney
Claims (4)
漿分離器に採血者の血管から血液をポンプ輸送する送血
ラインと、前記輸送された血液から前記模型血漿分離器
において前記血漿分離膜を通過した血漿が分離された赤
血球濃厚液を前記採血者の血管に返送する返送ラインと
、前記分離された血漿を系外に輸送する血漿ラインとよ
りなり、前記分離膜を経由するトランスメンブレン圧制
御が前記血漿ラインの内圧調整によって行われることを
特徴とする膜型血漿分離システム。(1) A membrane-type plasma separator equipped with a plasma separation membrane, a blood supply line that pumps blood from the blood collector's blood vessel to the membrane-type plasma separator, and a blood supply line that pumps blood from the blood sample to the model plasma separator. It consists of a return line that returns the red blood cell concentrate from which plasma has passed through the plasma separation membrane to the blood collector's blood vessel, and a plasma line that transports the separated plasma to the outside of the system, via the separation membrane. A membrane-type plasma separation system, characterized in that transmembrane pressure control is performed by adjusting the internal pressure of the plasma line.
れたクランプの開閉作動によって行われることを特徴と
する特許請求の範囲第１項記載の膜型血漿分離システム
。(2) The membrane plasma separation system according to claim 1, wherein the transmembrane pressure is controlled by opening and closing a clamp installed on the plasma line.
れた血漿ポンプの作動によって行われることを特徴とす
る特許請求の範囲第１項記載の膜型血漿分離システム。(3) The membrane plasma separation system according to claim 1, wherein the transmembrane pressure is controlled by the operation of a plasma pump installed in the plasma line.
ン圧との平均値、および血漿ライン圧との差圧として計
算されることを特徴とする特許請求の範囲第１項ないし
第３項記載の何れかの膜型血漿分離システム。(4) The transmembrane pressure is calculated as the average value of the blood supply line pressure and the return line pressure, and the differential pressure between the plasma line pressure and the plasma line pressure. Any membrane plasma separation system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59208674A JPS6185951A (en) | 1984-10-04 | 1984-10-04 | Membrane type serum separation system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59208674A JPS6185951A (en) | 1984-10-04 | 1984-10-04 | Membrane type serum separation system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6185951A true JPS6185951A (en) | 1986-05-01 |
Family
ID=16560178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59208674A Pending JPS6185951A (en) | 1984-10-04 | 1984-10-04 | Membrane type serum separation system |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6185951A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01113067A (en) * | 1987-10-27 | 1989-05-01 | Ube Ind Ltd | plasma separator |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5722764A (en) * | 1980-07-18 | 1982-02-05 | Kuraray Co | Double filtration type blood plasma separating exchanging device |
| JPS58206758A (en) * | 1982-05-28 | 1983-12-02 | 株式会社クラレ | Blood serum separation apparatus |
-
1984
- 1984-10-04 JP JP59208674A patent/JPS6185951A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5722764A (en) * | 1980-07-18 | 1982-02-05 | Kuraray Co | Double filtration type blood plasma separating exchanging device |
| JPS58206758A (en) * | 1982-05-28 | 1983-12-02 | 株式会社クラレ | Blood serum separation apparatus |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01113067A (en) * | 1987-10-27 | 1989-05-01 | Ube Ind Ltd | plasma separator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5217627A (en) | System and method for processing biological fluid | |
| CA2095623C (en) | System and method for processing biological fluids | |
| US5407425A (en) | System for the collecting and retransfusion of autologous blood | |
| CN101909671B (en) | Method for determining fistula recirculation and/or cardiopulmonary recirculation as a percentage of total fistula recirculation and cardiopulmonary recirculation | |
| EP0997158A2 (en) | Systems and methods for separating erythrocytes | |
| CN101269246B (en) | Continuous blood cleaning equipment with replacement liquid purifier | |
| US4639243A (en) | Process and apparatus for obtaining blood plasma | |
| JPH01500087A (en) | Methods and machines for blood separation by filtration for plasmapheresis procedures, plasma donation and sitapheresis, e.g. platelet apheresis | |
| IT8967853A1 (en) | EQUIPMENT FOR THE TREATMENT OF CELLS | |
| JPS6247366A (en) | Blood dialyzing and filtering apparatus | |
| JPH0611321B2 (en) | Cell suspension filtration device | |
| CN110072569A (en) | For the system of extracorporeal blood treatment, processing equipment, the operating method of external member and the system for extracorporeal blood treatment | |
| CA2079236C (en) | Multiple fluid source isolation, metering and alarm system and method | |
| US3459182A (en) | Blood administration method | |
| SE536054C2 (en) | Microbubble reducers to eliminate gas bubbles from a flow containing non-Newtonian fluid | |
| JP3148239B2 (en) | A device for penetrating drugs into red blood cells | |
| US20250269102A1 (en) | Plasmapheresis Methods | |
| Valbonesi et al. | Erythrothrombocytapheresis and plasmathrombocytapheresis with storage in T-sol of platelets collected by the new Amicus cell separator | |
| JP2003507149A (en) | Astrocyte device for biological treatment of circulating fluid | |
| Keshaviah et al. | Haemodialysis monitors and monitoring | |
| US20260131059A1 (en) | Dialysis system and methods | |
| CN1224624A (en) | blood filter | |
| JPH0628135Y2 (en) | Autologous blood recovery device | |
| JPS6036059A (en) | Serum sampling apparatus | |
| JPH0116180B2 (en) |